Literature DB >> 9070518

The efficacy of prophylaxis with low-dose warfarin for prevention of pulmonary embolism following total hip arthroplasty.

J R Lieberman1, J Wollaeger, F Dorey, B J Thomas, D J Kilgus, M J Grecula, G A Finerman, H C Amstutz.   

Abstract

The selection of a prophylaxis regimen and its implementation have been influenced considerably by the decreased duration of hospital stays and the pressures of cost containment. The purpose of the present study was to determine the rate of symptomatic pulmonary embolism both before and after discharge, the number of days required to achieve an adequate level of anticoagulation, and the complications associated with the use of low-dose warfarin after total hip arthroplasty. Between 1987 and 1993, 1099 primary and revision total hip arthroplasties were performed in 940 patients who received low-dose warfarin for prophylaxis against thromboembolic disease. The average duration of prophylaxis was fifteen days (range, one to twenty-nine days). The target level of anticoagulation (as indicated by a prothrombin time of fourteen to seventeen seconds) was achieved an average of three days (range, one to sixteen days) after the operation. The level of anticoagulation was lower than the target range at the time of discharge after 257 total hip arthroplasties (23.4 per cent), and the target level was never achieved during the period of hospitalization after fifty-four such procedures (4.9 per cent). Twelve total hip arthroplasties were associated with a symptomatic pulmonary embolism; the over-all prevalence of this complication therefore was 1.1 per cent (95 per cent confidence interval, 0.4 to 1.9 per cent). Four pulmonary emboli were diagnosed before discharge and eight, after discharge. A fatal pulmonary embolism occurred after one procedure (0.1 per cent). Patients who had a history of symptomatic venous thromboembolic disease had a significantly increased risk of symptomatic pulmonary embolism after total hip arthroplasty (p = 0.001, Fisher exact test). A major bleeding episode occurred after thirty-two total hip arthroplasties (2.9 per cent). Patients who had a prothrombin time of more than seventeen seconds had a significantly increased risk of hematoma formation (p = 0.003, chi-square analysis). Prophylaxis with low-dose warfarin is safe and effective for the prevention of pulmonary embolism after total hip arthroplasty.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9070518     DOI: 10.2106/00004623-199703000-00001

Source DB:  PubMed          Journal:  J Bone Joint Surg Am        ISSN: 0021-9355            Impact factor:   5.284


  13 in total

Review 1.  Management of venous thromboembolism in the elderly.

Authors:  Alex C Spyropoulos; Geno Merli
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

Review 2.  A benefit-risk assessment of dabigatran in the prevention of venous thromboembolism in orthopaedic surgery.

Authors:  Sam Schulman; Ammar Majeed
Journal:  Drug Saf       Date:  2011-06-01       Impact factor: 5.606

3.  Discontinuation of warfarin is unnecessary in total knee arthroplasty.

Authors:  David A Rhodes; Erik P Severson; Jeffrey T Hodrick; Harold K Dunn; Aaron A Hofmann
Journal:  Clin Orthop Relat Res       Date:  2010-01       Impact factor: 4.176

Review 4.  Measuring the outcomes and pharmacoeconomic consequences of venous thromboembolism prophylaxis in major orthopaedic surgery.

Authors:  Sean D Sullivan; Susan R Kahn; Bruce L Davidson; Lars Borris; Patrick Bossuyt; Gary Raskob
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

5.  Aspirin: an alternative for pulmonary embolism prophylaxis after arthroplasty?

Authors:  Ibrahim J Raphael; Eric H Tischler; Ronald Huang; Richard H Rothman; William J Hozack; Javad Parvizi
Journal:  Clin Orthop Relat Res       Date:  2014-02       Impact factor: 4.176

6.  VKORC1 variant genotypes influence warfarin response in patients undergoing total joint arthroplasty: a pilot study.

Authors:  Alejandro González Della Valle; Saurabh Khakharia; Charles J Glueck; Nicole Taveras; Ping Wang; Robert N Fontaine; Eduardo A Salvati
Journal:  Clin Orthop Relat Res       Date:  2008-11-26       Impact factor: 4.176

7.  Results of adjusted-dose heparin for thromboembolism prophylaxis in knee replacement compared to those found for its use in hip fracture surgery and elective hip replacement.

Authors:  David Yen; William Weiss
Journal:  Iowa Orthop J       Date:  2007

8.  Screening for deep vein thrombosis after periacetabular osteotomy in adult patients: is it necessary?

Authors:  Gregory G Polkowski; Stephen T Duncan; Adam D Bloemke; Perry L Schoenecker; John C Clohisy
Journal:  Clin Orthop Relat Res       Date:  2014-04-15       Impact factor: 4.176

Review 9.  Potent anticoagulants are associated with a higher all-cause mortality rate after hip and knee arthroplasty.

Authors:  Nigel E Sharrock; Alejandro Gonzalez Della Valle; George Go; Stephen Lyman; Eduardo A Salvati
Journal:  Clin Orthop Relat Res       Date:  2008-02-10       Impact factor: 4.176

10.  Interruption of long-term warfarin is not necessary in patients undergoing total hip arthroplasty.

Authors:  Mohamed Mussa; Pratheek Chikkalur; James Isbister; Shreeram Deshpande; Eric Isbister
Journal:  J Orthop       Date:  2019-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.